8-K current report · filed Nov 9, 2026

Tonix Pharmaceuticals Holding Corp. (TNXP) 8-K Current Report: November 9, 2026

Item 2.02Item EX-99.1TNXP overview

Short answer

Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Tonix announced operating results for the quarter ended September 30, 2026.

Tonix Pharmaceuticals Holding Corp. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Tonix announced operating results for the quarter ended September 30, 2026
  • Detailed financial figures and management commentary are in Exhibit 99.01, the accompanying earnings release

Item EX-99.1 · Exhibit EX-99.1

  • TONMYA net sales reached approximately $15.0 million, up 37% quarter-over-quarter, with prescriptions up 28% to 16,375
  • Coverage expanded to approximately 166 million lives, or 53% of U.S. covered lives, supporting commercial traction
  • Generic challenge from Dr. Reddy’s ANDA creates patent litigation risk to TONMYA’s revenue opportunity
  • Cash fell to $162.8 million from $207.6 million, while nine-month operating cash use reached $125.6 million
  • Third-quarter net loss widened to $53.3 million as R&D and SG&A increased to $25.8 million and $45.6 million respectively

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tonix Pharmaceuticals Holding Corp. 8-K filings

Get the next TNXP 8-K as it lands

Follow TNXP for push alerts, or ask the research agent what this filing means.